Anxiety and Ketamine: A More Complex Picture Than Depression
The evidence base for ketamine in major depression is robust and growing. The evidence base for ketamine in anxiety disorders is more complicated — and that complexity is worth understanding honestly rather than eliding.
This article is intended for patients and clinicians who want a clinically grounded, non-promotional overview of what is currently known.
Ketamine as an Anti-Anxiety Agent: The Basic Biology
Ketamine's primary mechanism — NMDA receptor antagonism and consequent glutamate modulation — has downstream effects on fear-related neural circuits. Preclinical research suggests that ketamine can reduce fear extinction deficits, which is relevant both to PTSD (where fear responses become dysregulated) and to certain anxiety presentations. Ketamine also reduces activity in hyperaroused amygdala circuits, at least acutely.
In clinical practice, many patients with co-occurring depression and anxiety — the most common presentation — experience reductions in anxiety symptoms alongside their depressive symptoms during a KAP course. This is consistent with what would be predicted from the neurobiology, and it is clinically significant.
What the Research Shows
Several small studies and case series have investigated ketamine for specific anxiety disorders:
- Social anxiety disorder: A small randomized trial (Glue et al., 2017) found that ketamine produced significant reductions in social anxiety symptoms. The effect was rapid but duration was variable.
- PTSD: Multiple studies support ketamine's efficacy in reducing PTSD symptom severity, particularly intrusive symptoms and hyperarousal. This is among the more robust anxiety-adjacent evidence bases.
- Generalized anxiety disorder (GAD): Clinical evidence is limited. Most studies examining ketamine for anxiety have included mixed or comorbid populations rather than patients with primary GAD.
- Panic disorder: Evidence is sparse. Anecdotal clinical reports exist but controlled trial data is very limited.
- OCD: There are preliminary findings suggesting ketamine may reduce OCD symptoms acutely, but the data is insufficient to draw clinical conclusions.
Where the Limits Lie
Most studies on ketamine and anxiety are small, use different dosing protocols, and involve mixed populations. The durability of anti-anxiety effects from ketamine is also less well established than for depression. Anxiety responses are also more variable — patients whose anxiety is tightly coupled to specific triggers or cognitive patterns may not find that ketamine addresses the underlying maintenance mechanisms without integrated psychotherapy.
For patients whose primary diagnosis is an anxiety disorder without significant co-occurring depression, the evidence base is currently insufficient to recommend KAP as a first- or second-line treatment. Candidacy for KAP in anxiety presentations requires careful clinical evaluation that considers the specific anxiety disorder, prior treatment response, and individual presentation.
The Integration Question
Anxiety is, in many ways, a disorder of avoidance. Ketamine can temporarily dissolve the psychological structures that maintain avoidance, creating a window in which new learning and exposure become more accessible. Whether that window is used productively depends heavily on what happens in integration — the psychotherapy work that follows the session. A ketamine session without skilled integration therapy is unlikely to produce lasting benefit for anxiety, and may in some cases reinforce helplessness if the patient has no framework for working with what emerged.
Clinical Bottom Line
Ketamine has genuine anti-anxiety properties and meaningful supporting evidence in anxiety presentations that co-occur with depression and in PTSD. For primary anxiety disorders without comorbid depression, the evidence is currently limited and evaluation must be highly individualized. Any patient considering KAP for anxiety should ensure they are working with a clinician capable of both the medical and psychotherapeutic dimensions of care.
Dr. (Andrew) Dror Rosenbach, MD — Mindful Pathways, Tel Aviv.
